برهم کنش هلیکوباکتر پیلوری و اتوفاژی: یک مکانیسم محتمل درگیر در سرطانزایی معده

محورهای موضوعی : باکتری شناسی

مرضیه اسمعیل زاده ¹ (دانشجوی دکتری تخصصی، گروه میکروبیولوژی، واحد جهرم، دانشگاه آزاد اسلامی، جهرم، ایران)
عباس یادگار ² (استادیار، مرکز تحقیقات بیماری های منتقله از آب و غذا، پژوهشکده بیماری های گوارش و کبد، دانشگاه علوم پزشکی شهید بهشتی، تهران، ایران.)
فرشید کفیل زاده ³ (استاد، گروه میکروبیولوژی، واحد جهرم، دانشگاه آزاد اسلامی، جهرم، ایران)
محمد کارگر ⁴ (استاد، گروه میکروبیولوژی، واحد جهرم، دانشگاه آزاد اسلامی، جهرم، ایران)
حمید اسدزاده عقدایی ⁵ (استادیار، مرکز تحقیقات علوم پایه و اپیدمیولوژی بیماری های دستگاه گوارش،پژوهشکده بیماری های گوارش و کبد، دانشگاه علوم پزشکی شهید)

تاریخ دریافت : 1399/05/27 تاریخ پذیرش : 1399/09/18 تاریخ انتشار : 1399/10/01

کلید واژه: سرطان معده, هلیکوباکتر پیلوری, اتوفاژی, CagA, VacA,

چکیده مقاله :

هلیکوباکتر پیلوری یک باکتری گرم منفی است که در بافت معده بیش از نیمی از جمعیت جهان استقرار یافت می‌شود و اصلی‌ترین عامل خطر برای ایجاد سرطان معده است. هلیکوباکتر پیلوری به عنوان شایع‌ترین پاتوژن باکتریایی در انسان می‌باشد و ارتباط معناداری بین عفونت هلیکوباکتر پیلوری و سرطان معده وجود دارد. اتوفاژی یک فرآیند حفاظتی مورد استفاده توسط سلول‌های یوکاریوتی برای حفظ هوموستازی سلول و دفاع در برابر حمله میکروب‌های پاتوژن است. هلیکوباکتر پیلوری می‌تواند موجب القای فرایند اتوفاژی در سلول‌های اپیتلیال معده و فاگوسیت‌های حرفه‌ای همچون ماکروفاژ‌ها و سلول‌های دندریتیک شود. پروتین‌های بازدارنده تومور مانند فسفاتازها، هومولوگ تنسین، P53 و پروتین رتینوبلاستوما با اثر مثبت موجب تنظیم اتوفاژی می‌شوند، در مقابل ترکیبات انکوژن از قبیلBCL-2 و مسیرهای AKT/TOR نقش بازدارندگی در فرآیند اتوفاژی دارند. با این وجود، ارتباط بین تنظیم اتوفاژی و فرآیند تومورزایی همچنان ناشناخته است. در هنگام عفونت هلیکوباکتر پیلوری و پس از القای اتوفاژی، باکتری می‌تواند از طریق تنظیم کاهشی پروتین‌های اتوفاژی از این فرآیند فرار و یا این که باکتری از اتوفاگوزوم به عنوان محل مناسبی برای بقای داخل سلولی استفاده کند. همچنین، اتوفاژی می‌تواند منجر به بقای سلولی یا مرگ سلولی در هنگام سرطان معده شود. در نتیجه، نقش عفونت هلیکوباکتر پیلوری در القا و یا مهار فرآیند اتوفاژی و تاثیر آن بر مسیرهای مرتبط با سرطان‌زایی معده یک موضوع مورد بحث است که نیازمند مطالعات بیشتر به منظور درک برهم کنش‌های میکروب و اتوفاژی می‌باشد.

چکیده انگلیسی:

Helicobacter pylori is a Gram-negative bacterium that colonizes the gastric tissue of more than half of the world's population and is the major risk factor for the development of gastric cancer.  H. pylori is the most common bacterial pathogen in humans, and there is a significant association  between H. pylori infection and gastric cancer. Autophagy is a protective process used by  eukaryotic cells to maintain cell homeostasis and defend against the attack of pathogenic    microbes. H. pylori can induce autophagy in epithelial cells of the stomach and professional  phagocytes such as macrophages and dendritic cells. Tumor inhibitory proteins including   phosphatases, PTEN, P53, and retinoblastoma protein have a positive effect on autophagy   regulation. In comparison, oncogenic products such as BCL-2 and AKT/TOR pathways play an inhibitory role on autophagy. However, the relationship between regulation of autophagy and   tumorigenesis is still unclear. During H. pylori infection and after the induction of autophagy, the bacterium can escape this process by downregulation of autophagy-related proteins, and/or use the autophagosome as a suitable niche for intracellular survival. In addition, autophagy can cause cell survival or cell death through the gastric cancer process. In conclusion, the role of H. pylori  infection in induction or inhibition of autophagy process, and its impact on gastric carcinogenic related pathways are a matter of controversy, which need further studies to understand the   interactions between the microbe and autophagy. 

منابع و مأخذ:

References
1. Tshibangu-Kabamba E, Yamaoka Y. Helicobacter pylori infection and antibiotic
resistance-from biology to clinical implications. Nature Reviews Gastroenterology &
Hepatology. 2021;18:613-29.
2. Malfertheiner P, Link A, Selgrad M. Helicobacter pylori: perspectives and time trends. Nature
Reviews Gastroenterology & Hepatology. 11(10):628-638.
3. Atherton JC, Blaser MJ. Coadaptation of Helicobacter pylori and humans: ancient history,
modern implications. Journal of Clinical Investigation. 2009;119:2475-87.
4. Hatakeyama M. Helicobacter pylori and gastric carcinogenesis. Journal of Gastroenterology.
2009;44:239-48.
5. Polk DB, Peek RM, Jr. Helicobacter pylori: gastric cancer and beyond. Nature Reviews Cancer.
2010;10:403-14.
6. Petersen AM, Krogfelt KA. Helicobacter pylori: an invading microorganism? A review. FEMS
Immunology and Medical Microbiology. 2003;36:117-26.
7. Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clinical
Microbiology Reviews. 2006;19:449-90
8. Oleastro M, Menard A. The Role of Helicobacter pylori outer membrane proteins in adherence
and pathogenesis. Biology. 2013;2:1110-34.
9. Ricci V. Relationship between VacA to in and host cell autophagy in Helicobacter pylori
infection of the human stomach: a few answers, many questions. To ins. 2016;8:203.
10. Palframan SL, Kwok T, Gabriel K. Vacuolating cytoto in A (VacA), a key to in for
Helicobacter pylori pathogenesis. Frontiers in Cellular and Infection Microbiology.
2012;2:92.
11. Yadegar A, Mohabati Mobarez A, ali MR. Genetic diversity and amino acid sequence
polymorphism in Helicobacter pylori CagL hypervariable motif and its association with
virulence markers and gastroduodenal diseases. Cancer Medicine. 2019;8:1619-32.
12. Phuc BH, Tuan VP, Dung HDQ, Binh TT, Tung PH, Tri TD, Thuan NPM, Khien VV, Trang
TTH, Akada J, Matsumoto T, Yamaoka Y. Helicobacter pylori type 4 secretion systems as
gastroduodenal disease markers. Scientific Reports 2021;11:4584.
13. Tegtmeyer N, Wessler S, Backert S. Role of the cag-pathogenicity island encoded type IV
secretion system in Helicobacter pylori pathogenesis. The FEBS Journal. 2011;278:
1190-1202.
14. Merino E, Flores-Encarnacion M, Aguilar-Gutierrez GR. Functional interaction and structural
characteristics of unique components of Helicobacter pylori T4SS. The FEBS Journal.
2017;284:3540-9.
15. Noto JM, Peek RM, Jr. The Helicobacter pylori cag pathogenicity island. Methods in
Molecular Biology. 2012;921:41-50.
16. Camorlinga-Ponce M, Romo C, Gonzalez-Valencia G, Munoz O, Torres J. Topographical
localisation of cagA positive and cagA negative Helicobacter pylori strains in the gastric
mucosa; an in situ hybridisation study. Journal of Clinical Pathology. 2004;57:822-8.
17. Wiedemann T, Hofbaur S, Tegtmeyer N, Huber S, Sewald N, Wessler S, Backert S, Rieder G.
Helicobacter pylori CagL dependent induction of gastrin e pression via a novel
v -integrin-integrin linked kinase signalling comple . Gut. 2012;61:986-96.
18. Noto JM, Peek RM, Jr. The Helicobacter pylori cag pathogenicity island. Methods in
Molecular Biology. 2012;921:41-50.
19. Murata-Kamiya N, Kikuchi K, Hayashi T, Higashi H, Hatakeyama M. Helicobacter pylori
e ploits host membrane phosphatidylserine for delivery, localization, and pathophysiological
action of the CagA oncoprotein. Cell Host Microbe. 2010;7:399-411.
20. Piscione P, Mazzone M, Marcantonio MCD, Muraro R, Mincione G. Eradication of
Helicobacter pylori and gastric cancer: a controversial relationship. Frontiers in
Microbiology. 2021;12:630852.

21. Hatakeyama M. Structure and function of Helicobacter pylori CagA, the first-identified
    bacterial protein involved in human cancer. Proceedings of the Japan Academy, Ser. B,
    Physical and Biological Sciences. 2017;93:196-219.
    22. Higashi H, Yokoyama K, Fujii Y, Ren S, Yuasa H, Saadat I, Murata-Kamiya N, Azuma T,
    Hatakeyama M. EPIYA motif is a membrane-targeting signal of Helicobacter pylori virulence
    factor CagA in mammalian cells. Journal of Biological Chemistry. 2005;280:23130-7.
    23. Saadat I, Higashi H, Obuse C, Umeda M, Murata-Kamiya N, Saito Y, Lu H, Ohnishi N,
    Azuma T, Suzuki A, Ohno S, Hatakeyama M. Helicobacter pylori CagA targets PAR1/MARK
    kinase to disrupt epithelial cell polarity. Nature. 2007;447:330-7.
    24. Noto JM, Peek RM. The role of microRNAs in Helicobacter pylori pathogenesis and gastric
    carcinogenesis. Frontiers in Cellular and Infection Microbiology. 2011;1:21.
    25. Chen CC, Liou JM, Lee YC, Hong TC, El-Omar EM, Wu MS. The interplay between
    Helicobacter pylori and gastrointestinal microbiota. Gut Microbes. 2021;13:1909459.
    26. Peek RM, Jr., Crabtree JE. Helicobacter infection and gastric neoplasia. The Journal of
    Pathology. 2006;208:233-48.
    27. Chang AH, Parsonnet J. Role of bacteria in oncogenesis. Clinical Microbiology Reviews.
    2010;23:837-57.
    28. Peek RM, Jr, Fiske C, Wilson KT. Role of innate immunity in Helicobacter pylori-induced
    gastric malignancy. Physiological Reviews. 2010;90:831-58.
    29. Backert S, Naumann M. What a disorder: proinflammatory signaling pathways induced by
    Helicobacter pylori. Trends in Microbiology. 2010;18:479-86.
    30. D'Elios MM, Andersen LP. Inflammation, immunity, and vaccines for Helicobacter pylori.
    Helicobacter. 2009;14:21-8.
    31. Wang CW, Klionsky DJ. The molecular mechanism of autophagy. Molecular Medicine.
    2003;9:65-76.
    32. Klionsky DJ, Cregg JM, Dunn WA, Jr., Emr SD, Sakai Y, Sandoval IV, Sibirny A, Subramani
    S, Thumm M, Veenhuis M, Ohsumi Y. A unified nomenclature for yeast autophagy-related
    genes. Developmental Cell. 2003;5:539-45.
    33. Morris DH, Yip CK, Shi Y, Chait BT, Wang QJ. Beclin 1-VPS34 comple architecture: understanding the nuts and bolts of therapeutic targets. Front Biol (Beijing). 2015;10:398-426.
    34. Rubinsztein DC, Codogno P, Levin B. Autophagy modulation as a potential therapeutic target
    for diverse diseases. Nature Reviews Drug Discovery. 2012;11:709-30.
    35. Tekirdag K, Cuervo AM. Chaperone-mediated autophagy and endosomal microautophagy:
    joint by a chaperone. Journal of Biological Chemistry. 2018;293:5414-24.
    36. Wirawan E, Vanden Berghe T, Lippens S, Agostinis P, Vandenabeele P. Autophagy: for
    better or for worse. Cell Research. 2012;22:43-61.
    37. Florey O, Overholtzer M. Autophagy proteins in macroendocytic engulfment. Trends in Cell
    Biology. 2012;22:374-80.
    38. Li C-J, Liao W-T, Wu M-Y, Chu P-Y. New insights into the role of autophagy in tumor
    immune microenvironment. International Journal of Molecular Sciences. 2017;18:1566.
    39. Deen NS, Huang SJ, Gong L, Kwok T, Devenish RJ. The impact of autophagic processes on
    the intracellular fate of Helicobacter pylori. Autophagy. 2013;9:639-52.
    40. Pyo JO, Nah J, Jung YK. Molecules and their functions in autophagy. E perimental &
    Molecular Medicine. 2012;44:73-80.
    41. Fougeray S, Pallet N. Mechanisms and biological functions of autophagy in diseased and
    ageing kidneys. Nature Reviews Nephrology. 2014;11:34-45.
    42. Castaño‐Rodríguez N, O Kaakoush N, Goh KL, Fock KM, Mitchel HM. Autophagy in
    Helicobacter pylori infection and related gastric cancer. Helicobacter. 2015;20:353-69.
    43. Kim KH, Lee MS. Autophagy-a key player in cellular and body metabolism. Nature Reviews
    Endocrinology. 2014;10:322-37.
    44. Wang YH, Wu JJ, Lei HY. The autophagic induction in Helicobacter pylori-infected
    macrophage. E perimental Biology and Medicine (Maywood, N.J.). 2009;234:171-80.
    45. Tsugawa H, Suzuki H. Reactive o ygen species-induced autophagic degradation of
    Helicobacter pylori CagA is specifically suppressed in cancer stem-like cells. Cell Host
    Microbe. 2012;12:764-77.
    46. Yahiro K, Satoh M. Low-density lipoprotein receptor-related protein-1 (LRP1) mediates
    autophagy and apoptosis caused by Helicobacter pylori VacA. Journal of Biological
    Chemistry. 2012;287:31104-15.
    47. Terebiznik M, Raju D. Effect of Helicobacter pylori’s vacuolating cytoto in on the autophagy
    pathway in gastric epithelial cells. Autophagy. 2009;5:370-9.
    48. Greenfield LK, Jones NL. Helicobacter pylori and its role in gastric carcinogenesis. Trends in
    Microbiology. 21:602-12.
    49. Li N, Tang B, Jia Yp, hu P, huang Y, Fang Y, Li Q, Wang K, hang W-J, Guo G, Wang
    T-J, Feng Y-J, Qiao B, Mao X-H, ou Q-M. Helicobacter pylori CagA protein negatively
    regulates autophagy and promotes inflammatory response via c-Met-PI3K/Akt-mTOR
    signaling pathway. Frontiers in Cellular and Infection Microbiology. 2017;7:417.
    50. Iqbal J, Kucuk C, deLeeuw RJ, Srivastava G, Tam W, Geng H, Klinkebiel D, Christman JK,
    Patel K, Cao K, Shen L, Dybkaer K, Tsui IFL, Ali H, Shimizu N, Au WY, Lam WL, Chan
    WC. Genomic analyses reveal global functional alterations that promote tumor growth and
    novel tumor suppressor genes in natural killer-cell malignancies. Leukemia. 2009;23:1139-51.
    51. Chen N, Debnath J. Autophagy and tumorigenesis. FEBS Letters. 2010;584:1427-35.
    52. Su , Yang , Xu Y, Chen Y, Yu Q. Apoptosis, autophagy, necroptosis, and cancer
    metastasis. Molecular Cancer. 2015;14:48.
    53. Kang MR, Kim MS, Oh JE, Kim YR, Song SY, Kim SS, Ahn CH, Yoo NJ, Lee SH.
    Frameshift mutations of autophagy-related genes ATG2B, ATG5, ATG9B and ATG12 in
    gastric and colorectal cancers with microsatellite instability. The Journal of Pathology.
    2009;217:702-6.
    54. Levy J, Cacheu W, Bara MA, L’Hermitte A, Lepage P, Fraudeau M, Trentesau C,
    Lemarchand J, Durand A, Crain AM, Marchiol C, Renault G, Dumont F, Letourneur F,
    Delacre M, Schmitt A, Terris B, Perret C, Chamaillard M, Couty JP, Romagnolo B. Intestinal
    inhibition of Atg7 prevents tumour initiation through a microbiome-influenced immune
    response and suppresses tumour growth. Nature Cell Biology. 2015;17:1062-73.
    55. Guo JY, Xia B, White E. Autophagy-mediated tumor promotion. Cell. 2013;155:1216-9.
    56. Mathew R, Kongara S, Beaudoin B, Karp CM, Bray K, Degenhardt K, Chen G, Jin S, White
    E. Autophagy suppresses tumor progression by limiting chromosomal instability. Genes &
    Development. 2007;21:1367-81.
    57. Wen J, hao Y, Guo L. Ore in A induces autophagy in HCT-116 human colon cancer cells
    through the ERK signaling pathway. International Journal of Molecular Medicine. 32-
    37:126;2015
    58. White E. Deconvoluting the conte t-dependent role for autophagy in cancer. Nature Reviews
    Cancer. 2012;12:401-10.
    59. Guanglin Qiu, Xuqi Li, Xiangming Ch , Chao Wei, Shicai He, Jing Lu, ongliang Jia, Ke
    Pang, Lin Fan. SIRT1 is a regulator of autophagy: Implications in gastric cancer progression
    and treatment. FEBS Letters. 2015;589:2034-42.
    60. Tu SP, Quante M, Bhagat G, Takaishi S, Cui G, Yang XD, Muthuplani S, Shibata W, Fo JG,
    Pritchard M, Wang TC. Interferon-γ inhibits gastric carcinogenesis by inducing epithelial cell
    autophagy and T cell apoptosis. Cancer Research. 2011;71:4247-59.
    61. Kim MS, Jeong EG, Ahn CH, Kim SS, Lee SH, Yoo NJ. Frameshift mutation of UVRAG, an
    autophagyrelated gene, in gastric carcinomas with microsatellite instability. Human Pathology.
    2008;39:1059-63.
    62. Ahn CH, Jeong EG, Lee JW, Kim MS, Kim SH, Kim SS, Yoo NJ. Lee SH. E pression of
    beclin-1, an autophagy-related protein, in gastric and colorectal cancers. APMIS.
    2007;115:1344-9.
    63. Yoshioka A et al. LC3, an autophagosome marker, is highly e pressed in gastrointestinal
    cancers. International Journal of Oncology. 2008;33:461-8.
    64. Guo JY, Chen HY, Mathew R, Fan J, Strohecker AM, Karsli-Uzunbas G, Kamphorst JJ, Chen
    G, Lemons JM, Karantza V, Coller HA, Dipaola RS, Gelinas C, Rabinowitz JD, White E.
    Activated Ras requires autophagy to maintain o idative metabolism and tumorigenesis. Genes
    & Development. 2011;25:460-70.
    65. Naumov GN, Folkman J, Straume O. Tumor dormancy due to failure of angiogenesis: Role of
    the microenvironment. Clinical & E perimental Metastasis. 2009;26:51-60.
    66. Choi AM, Ryter SW, Levine B. Autophagy in human health and disease. The New England
    Journal of Medicine. 2013;368:651-62.